Treatment of ADHD Using High and Low Frequency Paired Associative Deep Transcranial Magnet
This study investigates the effects of high and low-frequency paired associative deep transcranial magnetic stimulation (dTMS) on adults with Attention Deficit Hyperactivity Disorder (ADHD). The study aims to explore whether targeting the prefrontal cortex with paired stimulation can improve symptoms of ADHD by balanci
| Condition(s) | Attention Deficit Hyperactivity Disorder, Neurodevelopmental Disorders, Prefrontal Cortex Dysregulation, Cortical Arousal Imbalance |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This study investigates the effects of high and low-frequency paired associative deep transcranial magnetic stimulation (dTMS) on adults with Attention Deficit Hyperactivity Disorder (ADHD). The study aims to explore whether targeting the prefrontal cortex with paired stimulation can improve symptoms of ADHD by balancing cortical arousal between the brain hemispheres. A total of 90 participants with ADHD will be recruited. Participants with ADHD will undergo three weeks of daily TMS treatment, while participants who receive a sham treatment will be included for baseline comparisons. The study will measure electrophysiological, cognitive, and clinical outcomes using a variety of assessments, including EEG, cognitive tests, and CAARS to evaluate the treatment's efficacy. |
| Who can participate | Inclusion Criteria: * Men and women aged 21-65. * Aligned with the diagnosis of ADHD according to the criteria of the DSM-5. * Participants taking medication for the treatment of attention deficit hyperactivity disorder will be asked, starting one week before the start of the treatment until the end, to take Ritalin IR 10mg (provided that the taking of the medication will be done at least 8 hours before the start of the treatment or at least one hour after it. This instruction is also valid for taking the medication on the days of the follow-up sessions (4 and 8 weeks from the end of the daily treatment phase). Ritalin is given as the only option because a drug with a short half-life is needed. The dose can be increased up to 20 mg per dose). The choice of this drug is to ensure that chang |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Lead sponsor | Ben-Gurion University of the Negev |
| Locations | Beersheba, Israel |
| Start date | 2023-07-19 |
| NCT ID | NCT07105475 |
| Official listing | https://clinicaltrials.gov/study/NCT07105475 |